Julian Hubrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julian Hubrich has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Zorin
2 shared publicationsChristian Hagl
2 shared publicationsChristopher Herz
2 shared publicationsEmma Richert
2 shared publicationsJürgen Hörer
2 shared publicationsLinda Grefen
2 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (7)
Postoperative c-reactive protein resolution patterns in patients with and without postoperative atrial fibrillation after cardiac surgery
OBJECTIVES: Postoperative atrial fibrillation is common after cardiac surgery. Effective preventative measures are lacking, partly due to an incomplete understanding of its pathogenesis. Inflammation is a major contributor to postoperative atrial fibrillation development. This study aims to further characterize the association between systemic inflammation and postoperative atrial fibrillation. METHODS: A secondary analysis was conducted on a single-center cohort of patients undergoing cardiac surgery. The original study enrolled 405 cardiac surgery patients. After exclusion of patients with a history of persistent or permanent atrial fibrillation, patients undergoing heart transplantation and patients with incomplete interleukin measurements, 319 patients were included in the present analysis. Postoperative atrial fibrillation was identified through chart review and was defined as at least one AF episode lasting more than 30 seconds, as documented by telemetry or a 12-lead electrocardiogram during the patient’s initial hospitalization. Perioperative levels of interleukins and C-reactive protein were measured. The decline in C-reactive protein levels between postoperative days 3 and 10 was modelled using a linear regression. The association with postoperative atrial fibrillation and other outcomes after cardiac surgery was assessed using logistic and Tobit regression models. RESULTS: Of the 319 patients included in the study, 51% developed postoperative atrial fibrillation, most commonly on postoperative days 2 and 3. Cardiopulmonary bypass and intraoperative ventilation time were significantly associated with an increased risk of postoperative atrial fibrillation. Patients with postoperative atrial fibrillation had longer intensive care unit stays and longer times to extubation. C-reactive protein levels peaked on postoperative day 3 and declined more slowly in postoperative atrial fibrillation patients. A slower C-reactive protein decline was independently associated with postoperative atrial fibrillation (Odds ratio: 1.71, p = 0.046), prolonged postoperative intensive care unit length of stay and time to extubation. Interleukin-10 levels were significantly higher in patients with postoperative atrial fibrillation (Mean ratio: 1.28, p < 0.001). CONCLUSIONS: Postoperative atrial fibrillation is a prevalent complication after cardiac surgery and correlates with a slower postoperative C-reactive protein decline. This study suggests that postoperative atrial fibrillation is associated with delayed resolution of postoperative inflammation.
- 29 June 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (7)
Open AccessPostoperative c-reactive protein resolution patterns in patients with and without postoperative atrial fibrillation after cardiac surgery
OBJECTIVES: Postoperative atrial fibrillation is common after cardiac surgery. Effective preventative measures are lacking, partly due to an incomplete understanding of its pathogenesis. Inflammation is a major contributor to postoperative atrial fibrillation development. This study aims to further characterize the association between systemic inflammation and postoperative atrial fibrillation. METHODS: A secondary analysis was conducted on a single-center cohort of patients undergoing cardiac surgery. The original study enrolled 405 cardiac surgery patients. After exclusion of patients with a history of persistent or permanent atrial fibrillation, patients undergoing heart transplantation and patients with incomplete interleukin measurements, 319 patients were included in the present analysis. Postoperative atrial fibrillation was identified through chart review and was defined as at least one AF episode lasting more than 30 seconds, as documented by telemetry or a 12-lead electrocardiogram during the patient’s initial hospitalization. Perioperative levels of interleukins and C-reactive protein were measured. The decline in C-reactive protein levels between postoperative days 3 and 10 was modelled using a linear regression. The association with postoperative atrial fibrillation and other outcomes after cardiac surgery was assessed using logistic and Tobit regression models. RESULTS: Of the 319 patients included in the study, 51% developed postoperative atrial fibrillation, most commonly on postoperative days 2 and 3. Cardiopulmonary bypass and intraoperative ventilation time were significantly associated with an increased risk of postoperative atrial fibrillation. Patients with postoperative atrial fibrillation had longer intensive care unit stays and longer times to extubation. C-reactive protein levels peaked on postoperative day 3 and declined more slowly in postoperative atrial fibrillation patients. A slower C-reactive protein decline was independently associated with postoperative atrial fibrillation (Odds ratio: 1.71, p = 0.046), prolonged postoperative intensive care unit length of stay and time to extubation. Interleukin-10 levels were significantly higher in patients with postoperative atrial fibrillation (Mean ratio: 1.28, p < 0.001). CONCLUSIONS: Postoperative atrial fibrillation is a prevalent complication after cardiac surgery and correlates with a slower postoperative C-reactive protein decline. This study suggests that postoperative atrial fibrillation is associated with delayed resolution of postoperative inflammation.
- Open Access
- 22 November 2025
- Published by Elsevier in JTCVS Open
- Vol. 29, 101528
Biogenic polymer-based heart valve for congenital cardiac surgery
- 22 November 2025
- Published by Elsevier in JTCVS Open
- Vol. 29, 101528
Open AccessBiogenic polymer-based heart valve for congenital cardiac surgery
- 23 September 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (10)
Biogenic Polymers for Congenital Cardiac Surgery: In Vitro Durability Testing
Objectives: Currently available materials in congenital cardiac surgery (CCS) are far from optimal because they do not facilitate growth, remodelling, or renewal, resulting in poorer long-term outcomes due to material-related limitations. Bacterial cellulose (BC), a biogenic polymer-based material produced by Acetobacter xylinum, has emerged as a promising alternative exhibiting excellent bio- and haemocompatibility. This study aimed to develop BC specifically for application in CCS by modifying culturing conditions to enhance its biomechanical resilience. Methods: Bacterial cellulose was produced according to a standard protocol, and its biomechanical properties were evaluated using inflation pressure testing, thickness measurement, and uniaxial tensile testing. To improve these characteristics, 2 modifications, a change in the growth media composition and an extended incubation time, were implemented and subsequently evaluated in 5 further test series. The long-term durability of BC patches was assessed in a fatigue tester for 20 ± 0.5 million cycles, and potential structural damage was investigated using scanning electron microscopy. Results: Utilizing the 2 modifications, BC patches demonstrated a capability to reach and maintain pressures exceeding 1000 mm Hg with a durability of 100% (n = 24), compared to the standard 20.8% (n = 24) at 500 mm Hg. The maximum tensile strength was enhanced from 0.311 ± 0.057 megapascal (MPa) to 0.986 ± 0.397 MPa (P < .0001), with a thickness of 3.89 ± 0.95 mm (P < .0001). In the long-term durability testing, patches endured durations equalling 6 months without failure while retaining structural integrity. Conclusions: The potential of BC for use in CCS was demonstrated by enhancing its biomechanical properties through culturing modifications, warranting further investigation and development of the biomaterial.
- 23 September 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (10)
Biogenic Polymers for Congenital Cardiac Surgery: In Vitro Durability Testing
Objectives: Currently available materials in congenital cardiac surgery (CCS) are far from optimal because they do not facilitate growth, remodelling, or renewal, resulting in poorer long-term outcomes due to material-related limitations. Bacterial cellulose (BC), a biogenic polymer-based material produced by Acetobacter xylinum, has emerged as a promising alternative exhibiting excellent bio- and haemocompatibility. This study aimed to develop BC specifically for application in CCS by modifying culturing conditions to enhance its biomechanical resilience. Methods: Bacterial cellulose was produced according to a standard protocol, and its biomechanical properties were evaluated using inflation pressure testing, thickness measurement, and uniaxial tensile testing. To improve these characteristics, 2 modifications, a change in the growth media composition and an extended incubation time, were implemented and subsequently evaluated in 5 further test series. The long-term durability of BC patches was assessed in a fatigue tester for 20 ± 0.5 million cycles, and potential structural damage was investigated using scanning electron microscopy. Results: Utilizing the 2 modifications, BC patches demonstrated a capability to reach and maintain pressures exceeding 1000 mm Hg with a durability of 100% (n = 24), compared to the standard 20.8% (n = 24) at 500 mm Hg. The maximum tensile strength was enhanced from 0.311 ± 0.057 megapascal (MPa) to 0.986 ± 0.397 MPa (P < .0001), with a thickness of 3.89 ± 0.95 mm (P < .0001). In the long-term durability testing, patches endured durations equalling 6 months without failure while retaining structural integrity. Conclusions: The potential of BC for use in CCS was demonstrated by enhancing its biomechanical properties through culturing modifications, warranting further investigation and development of the biomaterial.